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1. Introduction 
Following retrovirus infection of a permissive cell, 
a double-stranded circular DNA intermediate is 
believed to be reverse-transcribed from the viral RNA 
genome and subsequently integrated into the host 
nuclear genome [ 11. Reverse transcription is carried 
out by a viral-coded RNAdependent DNA polymerase 
(reverse transcriptase) which copies the viral genome 
into DNA using a partially base-paired specific tRNA 
as primer [2-41. The integrated viral sequences are 
transcribed by the cell machinery giving rise to viral 
RNA. It has been shown that the intercalating drug 
ethidium bromide (EtBr) can inhibit the integration 
of retrovirus into the nuclear genome [5,6], as well 
as the expression of the provirus already integrated 
[7]. The same drug inhibits reverse transcriptase activ- 
ity in vitro f8]. 
We have been interested in the recognition of prim- 
er tRNATv by avian myeloblastosis virus (AMV) 
reverse transcriptase [9,10]. Evidence has been present- 
ed that the acceptor stem of primer tRNA is partially 
unwound by reverse tianscriptase, and we have pro- 
posed that this new function of reverse transcriptase 
can mediate the binding of primer tRNA to the viral 
genome [ II]. Here, we provide evidence that EtBr and 
the non-intercalating analogous tetramethylEtBr 
inhibit both the polymerase activity as well as the abil- 
ity of reverse transcriptase to unwind the acceptor 
stem of primer tRNA, while the formation of a stable 
complex between the enzyme and tRNA primer is 
abolished only by the intercalating drug. 
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2. Materials and methods 
2.1. Materiais 
AMV reverse transcriptase and virus were obtained 
from Dr J. W. Beard (Life Sciences, FL) and viral 35 S 
RNA was obtained from the viral pellets by phenol 
extraction [ 1 I]. Primer tRNATp from beef liver was 
purified as in [9]. Radioactive products were pur- 
chased from NEN. Synthetic polynucleotides were 
bought from Boehringer. EtBr and RNase T1 were from 
Sigma. EtBr dimer and tetramethylEtBr were kind 
gifts of Dr J. Paoletti and Dr J. B. LePecq (Villejuif). 
Polynucleotide kinase purified from T4 infected E. coli 
was a kind gift of Dr G. Keith (Strasbourg). 
2.2. Reverse transcrip tase assay 
(A) With poly(A-dT),z or poly(dA-dT)lz templates: 
In a final volume of 1 OOd the incubation mixture 
contained: 50 mM Tris-HCI (pH 8.3);40 mM KCI; 
6 mM MgCl*; 0.5 mM [ 3H]TTP (70 cpm/pmol); 
0.2 A260/ml of template and different amounts 
of enzyme, 
(B) With 35 S RNA-t RNATp template: The incu- 
bation mixture (100 ~1) contained Tris buffer, 
KC1 and MgCl* as above, including: 0.5 mM 
dATP, dCTP, dTTP and 5 PM d[32P]GTP (2000 
cpm/pmol); 0.15 Azao of 35 S AMV RNA and 
different amounts of enzyme. 
In both cases the incubation was carried out at 37°C 
for different lengths of time, The incubation was 
stopped by addition ofO.1 ml 20%cold trichloroacetic 
acid plus 0.1 M sodium pyrophosphate. The radioactive 
material was collected onto nitrocellulose membranes 
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and counted in a PPO-POPOP-toluene scintillation 
mixture. 
2.3. J-or $-End ~abe~~ng of tRNA 
Dephosphorylation and labeling of the 5’-end of 
tRNATm with polynucleotide kinase was done as 
described; labeling of the 3’-end adenosine of tRNA 
was done as in [ 1 I]. 
2.4. RMase T, digestion of 5’4abeled tRNA 
In a final volume of 0 .l ml the digestion mixture 
contained: 50 mM Tris-HCl (pH 7 S), 10 mM MgClz , 
45 pmol tRNA labeled as above, 0.6 units RNase Tr , 
and 60 units reverse transcriptase. Incubation was 
done at 37’C and the acid-precipitabIe .material deter- 
mined as for the polymerase assay. This experiment 
was also done in the presence of 200 I.cg/ml of bovine 
serum albumin to eliminate a possible adsorption of 
RNase Tr to the walls of the tube. 
2.5. ~ephadex C-l 00 chromatography of tRNA 7%~ - 
reverse transcrip Case complex 
The column (0.8 X 51 cm) was equilibrated in 100 
mM potassium phosphate buffer @H 7 5) containing 
5 mM Mg-acetate, 10 mM Z-mercaptoethanol, 0.1 mM 
EDTA, 0.1% Triton X-100 and 10% glycerol. V, was 
determined with dextran blue. Fractions of 0.5 ml 
were counted in 5 ml Bray’s scintillation mixture. 
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3. Results 
3 .l . Inhibition oj’polymerase activity 
The inhibitory effect of EtBr, EtBr dimer and the 
non-intercalating drug tetramethylEtBr are shown in 
fig.1 . Both polymerizing activities of reverse transcrip- 
tase, using an RNA or a DNA template are affected 
by the drugs. The most powerful inhibitor is the EtBr 
dimer which has been proven to have a very high affin- 
ity for nucleic acids. The same pattern of inhibition is 
obtained with EtBr or tetramethylEtBr using poly(A) 
or poly(dA) as templates, although higher concentra- 
tions of inhibitors are necessary to reach a given degree 
of inhibition with poly(A) than with poly(dA). 
In order to define the type of in~bition of reverse 
transcription by EtBr we have studied the effect of 
the drug at different concentrations of TTP. As seen 
in fig.2 it is shown that the inhibition by EtBr is non- 
competitive. Similar results were obtained with tetra- 
methylEtBr. 
3.2. Inhibition of primer tRNA recognition by reverse 
transcrip tase 
The partial unwinding of the acceptor stem of 
[““PI 5’-Iabeled primer tRNA was followed by assaying 
the accessibility to nuclease digestion of the 5’-termi- 
nal phosphate of tRNATp under different conditions. 
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Fig.1. Effect of EtBr, tetramethylEtBr and EtBr dimer on poly(dTf synthesis using poIy(A) [A] or polyfdil) [B] as template. The 
inset plot in f 1 A] corresponds to drug inhibition with the viral genome 35 S RNA as template. (*) EtBr dimer; (a) EtBr and (o) 
tetramethylEtBr. Amounts of enzyme used, 2 units (spee. act. 6 X IO4 units/mg). Other conditions are described in section 2. 
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Fig.2. Effect of EtBr (A) and tetramethylEtBr (0) on enzyme 
activity at various concentrations of TTP: drug concentration, 
5 PM; (0) control. Poly(A-dT),, was used as template. Recip- 
rocal plot according to Lineweaver and Burk. 
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Pig.3. Nuclease digestion of 5’4abeled tRNA”‘p with RNase 
T, : (0) plus 60 units reverse transcriptase; (B) plus 0.6 units 
RNase T, ; (a) plus reverse transcriptase, plus RNase T, ; (A) 
plus EDTA 1 mM, plus RNase T, ; (0) plus reverse transcrip- 
tase, plus RNase T,, plus EtBr 5 PM; (+) plus reverse tran- 
scriptase, plus RNase T, , plus tetramethylEtBr 10 PM. Other 
conditions we described in section 2. When EDTA was used 
no Mg” was added. 
RNase Tr alone are able to efficiently digest the 5’-end 
of tRNA. Together they led to a dramatic loss of radio- 
activity. The digestion of the ?-terminal phosphate 
of tRNA by RNase T, in the presence of reverse tran- 
scriptase is greatly diminished if EtBr or tetramethyl- 
EtBr are present. No difference was observed in the 
presence of bovine serum albumin. Moreover in the 
presence of EDTA total digestion was reached, RNase 
Tr being the only protein present in the mixture. 
When complex formation between primer tRNA 
and reverse transcriptase was followed by gel filtration 
in the presence of EtBr or tetramethylEtBr, the results 
shown in fig.4 were obtained. No stable complex was 
detected in the presence of EtBr while tetramethyl- 
EtBr did not affect complex formation a similar situa- 
tion to the one obtained in the absence of drug. 
4. Discussion 
Genomic viral RNAextracted from AMV is partially 
base-paired to tRNATm. DNA synthesis is initiated 
from the 3’-end of this primer tRNA [2,3]. Our studies 
of the specificity of interaction between AMV reverse 
transcriptase and primer tRNATm led us to propose 
the hypothesis that partial unwinding of the acceptor 
stem of tRNA by the viral polymerase may be impor- 
tant in positioning the primer on the viral genome [ 111. 
Strong intercalation of EtBr in the acceptor stem 
of tRNAhas been described [ 141. As this intercalation 
must lead to the stabilization of the acceptor stem, 
we felt it could be interesting to study the effect of 
EtBr on the recognition of primer tRNA by reverse 
transcriptase. Our results indicate that the partial 
unwinding of tRNA is strongly inhibited by EtBr and 
the non-intercalating drug tetramethylEtBr, while 
complex formation is only impaired by EtBr. The 
inhibitory effect of tetramethylEtBr on the polymer- 
izing activities of the enzyme can be ascribed to a 
direct interaction of the drug and the polymerase, 
whereas the lack of complex formation in the presence 
of EtBr may be related to the intercalation of the drug 
and changes in the tertiary structure of tRNATrP by 
EtBr. Thus, tetramethylEtBr which is not intercalated, 
does not affect complex formation under the same 
conditions. 
This in vitro inhibition of reverse transcriptase by 
EtBr may be related to the inhibition of virus integra- 
tion by this drug, as in the case of avian sarcoma- 
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Fig.4. Sephadex G-100 chromatography of reverse transcriptase-tRNA”rp complex. Reverse transcriptase (150 units) and t[ ‘HI- 
RNA (labeled at the terminal adenosine, 10 pmol 1390 cpm/pmol) were submitted to gel chromatography as in section 2 in the 
presence or absence of 5 PM EtBr or 10 PM tetramethylEtBr: (0) enzyme plus tRNA; (a) plus tetramethylEtBr; (o) plus EtBr; 
(A) tRNA alone. 
infected cells [5,6]. The inhibition of the partial 
unwinding of the acceptor stem of tRNA by EtBr can 
be related to the in vivo inhibitory effect of the drug 
on infectious virus production in cells containing the 
integrated provirus [7]: the impairment of the inter- 
action between tRNAprimer and reverse transcriptase 
would lead to the encapsidation of viral RNA lacking 
the natural primer, which could then be incapable of 
integration into the nuclear genome. 
The main characteristic of reverse transcriptase is 
to recognize a natural or synthetic RNA template. 
Since animal DNA polymerase y is able to efficiently 
copy a poly(A)-oligo(dT) template, the two enzymes 
were at one time thought to be related. It is currently 
clear that the two polymerases are in fact different 
enzymes [ 121. Yet reverse transcriptase and DNA 
polymerase y ,unlike other DNA polymerases, are both 
strongly inhibited in vitro by EtBr [8,13], Although 
the degree of inhibition is comparable, a different 
mechanism seems to be involved, 
Intercalation is essential in the inhibition of poly- 
merase y by the drug [13]; this is not the case for 
reverse transcriptase: the non-intercalating agent 
tetramethylEtBr strongly inhibited this enzyme (fig.1). 
We have confirmed that intercalated EtBr does not 
inhibit reverse transcriptase activity with a template 
poly(dC)-oligo(dG) [8] under the same conditions 
that DNA polymerase y is strongly inhibited [ 131. If 
we assume that the drug interacts with the enzyme, 
we can speculate that poly(dA)-oligo~dT) and poly- 
(dC)-oligo(dG) can interact differently with reverse 
transcriptase and that in the latter case the enzyme 
target site for EtBr is not accessible to the drug. 
Furthermore in the case of reverse transcriptase, 
the inhibition obtained at varying concentration of 
TTP isnon-~om~titive (fig.21 for EtBr and tetrameth- 
ylEtBr, whereas the inhibition of DNA polymerase 
y under the same conditions is clearly competitive [ 121. 
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